CosIng Checker
CosIng Checker
EU cosmetic ingredients, restrictions and safety
Login
Official EU label nameGlossary entry 8675

DIHYDROCOUMARIN

This record confirms an official common ingredient name for EU cosmetic product labelling. It does not by itself confirm that the substance is permitted, unrestricted or safe.

Global evidence snapshot

The resolved identity has matching regulatory evidence in 9 of 13 indexed market datasets: 9 country records and 0 EU Annex records. Every result and evidence gap is listed below.

9 markets with evidence
Markets checked
13
Markets with evidence
9
Evidence gaps
4
Resolved identifiers
2

A missing local match is not permission, approval or proof of safety. It means no strong identity match was resolved in that indexed dataset.

Resolved substance identity

CAS:119-84-6
EC:204-354-9
Ingredient index records:
DIHYDROCOUMARIN
Cosmetic functions: FRAGRANCE, PERFUMING

Inventory restriction note: II/427

Open full local profile
8 matched or reported names
DIHYDROCOUMARIN3,4-Dihydrocoumarin, when used as a fragrance ingredientDihydrocoumarinDihydrocoumarin, when used as a fragrance ingredient.3,4-二氢香豆素 — 3,4-Dihydrocoumarine （CAS No. 119-84-6）디하이드로쿠마린Dihidrocumarina, quando usado como ingrediente de fragrância.3,4-Dihydrocoumarin (CAS No. 119-84-6), when used as a fragrance ingredient.

Regulatory evidence in all 13 markets

Open each matched record for its scope, concentration, conditions, warnings and official source version.

Swipe or scroll horizontally to see dataset coverage and next actions.

MarketResultRecordsDatasetMeaning / next action
European Union
EU
No local match0
Complete annex dataset
Regulation (EC) 1223/2009 consolidated to 1 May 2026
No annex match only means that these five annexes did not return a match; CosIng identity data and other EU obligations still need review.
Great Britain
GB
Prohibited1Open record 1
Complete consolidated annex dataset
GB retained Regulation 1223/2009 schedules, effective 15 August 2026
Review every linked record and exact conditions.
Canada
CA
Restricted1Open record 1
Complete Hotlist snapshot
Health Canada Cosmetic Ingredient Hotlist, 13 August 2025
Review every linked record and exact conditions.
New Zealand
NZ
Prohibited1Open record 1
Complete schedules dataset
Cosmetic Products Group Standard schedules effective 1 January 2026
Review every linked record and exact conditions.
ASEAN
ASEAN
Prohibited1Open record 1
Complete regional annex dataset
ASEAN Cosmetic Directive annexes 2026-1, 22 June 2026
Review every linked record and exact conditions.
China
CN
Prohibited1Open record 1
Complete prohibited catalogues plus official-source workflow
NMPA 2021 banned catalogues plus dynamic IECIC List I/List II system current since 2025
Review every linked record and exact conditions.
Japan
JP
No local match0
Complete Standards appendices dataset
MHLW Standards for Cosmetics official English source and Japanese amendments checked for the imported snapshot
The Japanese text and subsequent notices are canonical; no local match is not a product-compliance conclusion.
South Korea
KR
Prohibited1Open record 1
Complete current appendix dataset
MFDS Notice 2026-19, effective 18 March 2026
Review every linked record and exact conditions.
United States
US
No local match0
Complete enumerated federal ingredient rules
eCFR Title 21 issue date 27 August 2026
FDA has no general approved-cosmetic-ingredient catalogue; absence from these sections is not approval or proof of safety.
Australia
AU
No local match0
Complete cosmetic-relevant Poisons Standard subset plus official workflow
Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026
An AICIS Inventory match is not cosmetic approval; no Inventory match can indicate a new, exempted, reported or confidential introduction.
Brazil
BR
Prohibited1Open record 1
Complete prohibited dataset plus current restricted-list workflow
ANVISA RDC 1.029/2026 and RDC 1.030/2026, published 15 June 2026
Review every linked record and exact conditions.
India
IN
Prohibited1Open record 1
Complete current Part 2 dataset plus official workflow for Parts 1, 3 and 4
Cosmetics Rules 2020 plus current BIS IS 4707 parts (1:2020, 2:2025, 3:2025, 4:2022)
Review every linked record and exact conditions.
Saudi Arabia
SA
Prohibited1Open record 1
Complete official list index
SFDA live prohibited/restricted lists, snapshot 30 August 2026
Review every linked record and exact conditions.
No market rows match this filter.

Matching market records and conditions

Chemical identity and properties

PubChem 2D chemical structure for CAS 119-84-6
CAS 119-84-6PubChem CID 660

Dihydrocoumarin

3,4-dihydrocoumarin is a chromanone that is the 3,4-dihydro derivative of coumarin. It has a role as a plant metabolite. It is functionally related to a coumarin. — ChEBI

IUPAC name
3,4-dihydrochromen-2-one
Molecular formula
C9H8O2
Molecular weight
148.16 g/mol
Exact mass
148.052429494 Da
XLogP3
1.6
Topological polar surface area
26.3 Ų
Hydrogen-bond donors
0
Hydrogen-bond acceptors
2
Covalent units
1
Defined stereocentres
0

Also known as

3,4-dihydrocoumarinhydrocoumarinBenzodihydropyronemelilotin2-chromanone1,2-benzodihydropyronemelilotic lactoneMelilotine
16 more reported names
Oxochroman2H-1-Benzopyran-2-one, 3,4-dihydro-Chroman, 2-oxo-DihydrobenzopyroneUsaf do-12Coumarin, 3,4-dihydro-Meliotine2-Hydroxydihydrocinnamic acid lactoneNCI-C55890o-hydroxydihydrocinnamic acid lactoneFEMA No. 2381Hydrocinnamic acid, o-hydroxy-, delta-lactoneNM5K1Y1BT2CHEBI:16151NSC-10121RefChem:91117
Open full PubChem recordPubChem annotations3D structure image
External database identifiers

Evidence from additional scientific databases

NIH PubChem PUG-View
Exact identifier match660

Attributed physical-property, hazard, environmental and use annotations.

  • Substance: 3,4-Dihydrocoumarin Source: NTP Technical Reports
  • NTP Technical Report: TR-423: Toxicology and Carcinogenesis Studies of 3,4-Dihydrocoumarin (CASRN 119-84-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies) (1993 ) Source: NTP Technical Reports
  • Peer Review Date: 06/23/92 Source: NTP Technical Reports
  • Conclusion for Male Rat: Some Evidence Source: NTP Technical Reports
  • Conclusion for Female Rat: No Evidence Source: NTP Technical Reports
  • Conclusion for Male Mice: No Evidence Source: NTP Technical Reports
  • Conclusion for Female Mice: Some Evidence Source: NTP Technical Reports
  • Summary: Under the conditions of these 2-year gavage studies, there was some evidence of carcinogenic activity of 3,4-dihydrocoumarin in male F344/N rats based on increased incidences of renal tubule adenomas and focal hyperplasia. The transitional cell carcinomas in two 600 mg/kg males may also have been chemical related. There was no evidence of carcinogenic activity of 3,4-dihydrocoumarin in female F344/N rats receiving 150, 300, or 600 mg/kg. There was no evidence of carcinogenic activity of 3,4-dihydrocoumarin in male B6C3F1 mice receiving 200, 400, or 800 mg/kg. There was some evidence of carcinogenic activity in female B6C3F1 mice based on increased incidences of hepatocellular adenoma and hepatocellular adenoma or carcinoma (combined).; 3,4-Dihydrocoumarin caused ulcers, hyperplasia, and inflammation of the forestomach, parathyroid gland hyperplasia, and increased severity of nephropathy in male rats. Source: NTP Technical Reports
  • First Aid: EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.; SKIN: IMMEDIATELY flood affected skin with water while removing and isolating all contaminated clothing. Gently wash all affected skin areas thoroughly with soap and water. If symptoms such as redness or irritation develop, IMMEDIATELY call a physician and be prepared to transport the victim to a hospital for treatment.; INHALATION: IMMEDIATELY leave the contaminated area; take deep breaths of fresh air. If symptoms (such as wheezing, coughing, shortness of breath, or burning in the mouth, throat, or chest) develop, call a physician and be prepared to transport the victim to a hospital. Provide proper respiratory protection to rescuers entering an unknown atmosphere. Whenever possible, Self-Contained Breathing Apparatus (SCBA) shou Source: CAMEO Chemicals
  • Signal: Warning Source: European Chemicals Agency (ECHA)
  • GHS Hazard Statements: H302 (> 99.9%): Harmful if swallowed [Warning Acute toxicity, oral]; H317 (97.4%): May cause an allergic skin reaction [Warning Sensitization, Skin] Source: European Chemicals Agency (ECHA)
  • Precautionary Statement Codes: P261, P264, P270, P272, P280, P301+P317, P302+P352, P321, P330, P333+P317, P362+P364, and P501 (click each P-code to see the statement) Source: European Chemicals Agency (ECHA)
  • ECHA C&L Notifications Summary: Aggregated GHS information provided per 1702 reports by companies from 11 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. Source: European Chemicals Agency (ECHA)
  • Signal: Warning Source: Hazardous Chemical Information System (HCIS), Safe Work Australia
  • GHS Hazard Statements: H302: Harmful if swallowed [Warning Acute toxicity, oral]; H317: May cause an allergic skin reaction [Warning Sensitization, Skin] Source: Hazardous Chemical Information System (HCIS), Safe Work Australia
  • Precautionary Statement Codes: P261, P264, P270, P272, P280, P301+P317, P302+P352, P321, P330, P333+P317, P362+P364, and P501 (click each P-code to see the statement) Source: Hazardous Chemical Information System (HCIS), Safe Work Australia

Mapped by: Existing checksum-valid CAS to unique PubChem CID match. Retrieved: 2026-08-31. Open source record

Scientific classifications and hazard annotations provide context and do not replace the market-specific regulatory decision shown above.

Additional source coverage and match status
SourceResultChecked
NIH PubChem PUG-ViewExact match2026-08-31

A recorded no-match is useful evidence that the source was checked; it is not a claim that the substance does not exist elsewhere.

Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

Additional authoritative substance research

These source-specific lookups can add hazard, toxicology, identity and assessment context. A link is a research route, not a claim that the source contains an exact record.

Cosmetic Ingredient Review safety assessments

Expert Panel conclusions, assessed ingredient groups, use conditions, dates and report documents

Independent expert review considered by FDA; not a government approval or binding market rule

Research this identity

FDA Global Substance Registration System

UNII identifiers, preferred names, substance types, codes and public substance relationships

Identity registry only; UNII availability does not imply FDA review or approval

Research this identity

ILO/WHO International Chemical Safety Cards

Hazards, symptoms, first aid, storage, incompatibilities and physical properties for covered chemicals

International occupational chemical-safety reference; not cosmetic-use approval

Research this identity

Japan NITE-CHRIP

Chemical identity, Japanese and foreign legal lists, GHS hazards and exposure-related information

Chemical-management evidence; cosmetic status remains governed by the applicable MHLW standard and market rules

Research this identity

NIOSH Pocket Guide to Chemical Hazards

REL, PEL, IDLH, properties, exposure routes, symptoms, target organs, first aid and measurement methods for covered workplace chemicals

US occupational-health guidance and limits; not a cosmetic ingredient decision

Research this identity

OECD eChemPortal

Gateway to authority-owned physical-property, fate, ecotoxicity, toxicity, exposure and GHS records

Discovery gateway; each linked authority remains responsible for its data

Research this identity

US EPA CompTox CTX APIs

DTXSID identity, experimental and predicted properties, toxicity, bioactivity, exposure and environmental data

Scientific and computational evidence; predictions must remain labelled and do not determine cosmetic legality

Research this identity

Continue the compliance check

1. Confirm identity

Match the supplier specification, CAS/EC identifiers and composition to this official label name. Similar wording is not proof of chemical equivalence.

2. Review restrictions

Check every exact Annex record shown above, plus CMR, nanomaterial, SCCS and later-amendment requirements that may apply.

3. Verify the formula

Evaluate concentration, product type, purity, warnings, claims and each target market before making a compliance decision.

Screen in a formulaOpen standalone comparison

Official source and scope

Imported from Commission Implementing Decision (EU) 2025/1175 (dataset version EU 2025/1175). The glossary supplies common ingredient names for the ingredient list required by Article 19(1)(g); it is not an approval or safety list.

Open official Decision